Phreesia, Inc. (NYSE:PHR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analyst consensus: Nineteen analysts assign an average rating of "Moderate Buy" (12 buys, 6 holds, 1 sell) with a 12‑month average price target of $22, though several firms recently cut targets sharply (Truist $11, BMO $14, Needham $14) while RBC initiated at $26.
• Insider and institutional activity: Insiders sold 40,367 shares worth about $613,251 in the last 90 days (insiders own ~5.5%), and institutional/hedge fund ownership is very high at ~92.1% with several funds materially increasing positions.
• Recent results and valuation: Q1 revenue rose 15.9% to $127.1M but EPS missed at $0.02 versus a $0.07 estimate, shares are trading near their 52‑week low (~$8) with a market cap of ~$490M and a high trailing PE (~269), and analysts forecast -1.1 EPS for the year.

Phreesia, Inc. (NYSE:PHR - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nineteen analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $22.00.

PHR has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Phreesia from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. Truist Financial reaffirmed a "hold" rating and set a $11.00 price target (down from $24.00) on shares of Phreesia in a research report on Tuesday, March 31st. BMO Capital Markets decreased their price objective on Phreesia from $32.00 to $14.00 and set an "outperform" rating on the stock in a report on Tuesday, March 31st. Needham & Company LLC lowered their price objective on Phreesia from $35.00 to $14.00 and set a "buy" rating for the company in a research report on Tuesday, March 31st. Finally, Royal Bank Of Canada started coverage on Phreesia in a research note on Friday, January 9th. They set a "moderate buy" rating and a $26.00 target price for the company.

Insider Activity

In other Phreesia news, insider Evan Roberts sold 6,268 shares of the company's stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $102,544.48. Following the transaction, the insider owned 826,554 shares of the company's stock, valued at $13,522,423.44. This represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider David Linetsky sold 6,038 shares of Phreesia stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $16.36, for a total transaction of $98,781.68. Following the sale, the insider owned 223,942 shares of the company's stock, valued at approximately $3,663,691.12. This represents a 2.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 40,367 shares of company stock worth $613,251. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Phreesia

Several large investors have recently made changes to their positions in PHR. Granahan Investment Management LLC raised its position in Phreesia by 73.8% in the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company's stock valued at $40,601,000 after purchasing an additional 1,018,987 shares during the period. Prosight Management LP purchased a new position in shares of Phreesia during the fourth quarter worth $16,533,000. Millennium Management LLC boosted its position in shares of Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company's stock worth $25,028,000 after buying an additional 936,033 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Phreesia in the fourth quarter valued at $15,213,000. Finally, Greenhouse Funds LLLP grew its stake in shares of Phreesia by 16.8% in the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company's stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Stock Down 0.3%

Shares of PHR opened at $8.06 on Friday. Phreesia has a 52-week low of $7.77 and a 52-week high of $32.76. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.41. The stock has a fifty day simple moving average of $11.32 and a two-hundred day simple moving average of $16.81. The company has a market capitalization of $489.97 million, a PE ratio of 268.80 and a beta of 0.86.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm had revenue of $127.07 million for the quarter, compared to analyst estimates of $126.75 million. During the same period in the previous year, the firm posted ($0.11) EPS. The company's revenue was up 15.9% compared to the same quarter last year. As a group, equities analysts forecast that Phreesia will post -1.1 EPS for the current year.

Phreesia Company Profile

Phreesia, Inc NYSE: PHR is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company's cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.